Faster, better, together: Biopharma collaboration trends in the pandemic, and the future of medicine

Register & watch

The strategic collaborations born out of the efforts to help address the COVID-19 pandemic have offered a wealth of insight into how the biopharma industry will continue to change in the years to come. Companies across the supply chain—from raw materials and technology suppliers to biomanufacturers—view collaboration as a critical strategy to advancing biologics research, scale-up and manufacturing for all biologics development.

Register and join Avantor and C&EN for a webinar featuring Avantor subject matter experts and guest industry speakers, discussing the benefits of partnership and collaboration.

This webinar event, hosted by C&EN, took place, October 27, 2021

Register & watch

Speakers:

Justin Moran, PhD

Executive Director, Head of Early Bioprocess Development
Pfizer Vaccines

The Impact of a Pandemic on Process Development

Nandu Deorkar, PhD

Vice President, R&D - Bioprocessing
Avantor

A collaborative ecosystem to accelerate the commercial manufacturing of novel vaccines and other therapeutics

Jennifer Grossman, PhD

Business Development Manager, Pilot Bioproduction Facility
Walter Reed Army Institute of Research

Lessons on flexibility and scaling-up fast: how the biopharmaceutical industry is preparing to face the next pandemic

Claudia Berrón, MBA

Senior Vice President, Avantor Clinical Services
Avantor

The impact of decentralization and digitization on clinical trial logistics, kits, and sample management

Pranav Vengsarkar, PhD

Manager, Process Development, Research Biopharma Production
Avantor

Enhanced raw material delivery strategies: Debottlenecking of buffer and media preparation in mAbs and novel therapeutics

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.